Skip to main content
Erschienen in: Supportive Care in Cancer 8/2010

01.08.2010 | Letter to the Editor

Increased blood culture sensitivity in pediatric oncology patients: is it the peripheral culture or increased collected blood volume?

verfasst von: Thomas V. Adamkiewicz

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Excerpt

Scheinemann et al. [3] re-examined retrospectively the occurrence of central vs. peripheral blood cultures on the same oncology ward where a similar study was conducted previously [1]. The principal observation from the original study was that peripheral blood cultures were seldom clinically useful as a means to identify central line infections. However, both studies showed that the addition of a peripheral culture overall improves sensitivity to detect true pathogens. As Scheinemann et al. pointed out, it is possible that the same could have been achieved by drawing a larger blood draw from a single site. Indeed, in a recent study, pediatric blood cultures with measured volume ≥4 ml in children ≥36 months yielded significantly more positive results [2]. Scheinemann et al. defined 1 to 3 ml as an adequate collection volume, at time of collection. Volumes were not confirmed after collection. Adding a peripheral culture would have doubled the total volume collected and increased the likelihood of recovering a pathogen. Also, peripheral blood cultures contributed to the cumulative likelihood of isolating contaminants, thus the lowering of overall specificity. In the context where optimal blood volumes are collected from central lines, the utility of peripheral blood cultures still can be questioned. A well-designed prospective study to help determine best blood culture collection practices in pediatric oncology patients is needed. Effects of volume, timing (single vs. tandem draw), and site (central vs. peripheral) would be examined separately. Such a study should include sampling before and after start of antibiotic therapy, as positive culture rates remain significant after antibiotics are started [1], and presence of antibiotics may change culture recovery conditions. Such a study could include repeated central line cultures as control, an approach that could also help identify contaminants. …
Literatur
1.
Zurück zum Zitat Adamkiewicz TV, Lorenzana A, Doyle J, Richardson S (1999) Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 18(6):556–558CrossRefPubMed Adamkiewicz TV, Lorenzana A, Doyle J, Richardson S (1999) Peripheral vs. central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 18(6):556–558CrossRefPubMed
2.
Zurück zum Zitat Connell TG, Rele M, Cowley D, Buttery JP, Curtis N (2007) How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics 119(5):891–896CrossRefPubMed Connell TG, Rele M, Cowley D, Buttery JP, Curtis N (2007) How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics 119(5):891–896CrossRefPubMed
3.
Zurück zum Zitat Scheinemann K, Ethier MC, Dupuis LL, Richardson SE, Doyle J, Allen U, Sung L (2009) Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line. Support Care Cancer. doi:10.1007/s00520-009-0725-0 Scheinemann K, Ethier MC, Dupuis LL, Richardson SE, Doyle J, Allen U, Sung L (2009) Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line. Support Care Cancer. doi:10.​1007/​s00520-009-0725-0
Metadaten
Titel
Increased blood culture sensitivity in pediatric oncology patients: is it the peripheral culture or increased collected blood volume?
verfasst von
Thomas V. Adamkiewicz
Publikationsdatum
01.08.2010
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0872-3

Weitere Artikel der Ausgabe 8/2010

Supportive Care in Cancer 8/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.